ATRA

Atara BiotherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$9.50

Analysis reference price unavailable

Analysis 2026-07-28 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$6.70

Analysis reference price unavailable

Analysis 2026-07-28 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$4.50

Analysis reference price unavailable

Analysis 2026-07-28 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-28

AI commentary

News flow is concentrated on Q1 results, the potential tab-cel regulatory path and corporate updates. Social sentiment, options skew, short interest and employee-rating data are unavailable rather than genuinely neutral; the sentiment fields above therefore carry low informational weight. Analyst revisions and target changes are also unavailable. The deterministic prior remains negative, supporting cautious event monitoring rather than a confirmed recovery thesis.

RankAlpha Sentiment Codex - 2026-07-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-26eventPotential tab-cel BLA resubmission pathHigh impact

Atara reported a productive FDA meeting in which a single-arm study using an appropriate historical control could support a potential tab-cel resubmission. Pierre Fabre plans additional data, with Atara expecting a further regulatory update in Q3 2026. Execution and timing remain uncertain. [#PR-EARNINGS-2026-05-13]

2026-10-26catalystLow recurring revenue and financing overhangHigh impact

Q1 2026 revenue was $0.5 million and net loss was $4.1 million, while the prior-year comparison benefited from a one-time revenue acceleration. The limited recurring revenue base leaves the stock sensitive to regulatory delays, cash use and future financing needs. [#SEC-8K-2026-05-12]

2027-07-28catalystRunway extension and operating-cost resetHigh impact

Cash, cash equivalents and short-term investments totaled $8.4 million at March 31, 2026; Atara said $4.8 million of subsequent ATM proceeds and operating efficiencies should fund planned operations into mid-2027. Financing dependence and dilution remain offsets. [#PR-EARNINGS-2026-05-13]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-28 • Updated nightlySource: Internal modelMethodology